wr 33278 has been researched along with amifostine anhydrous in 12 studies
| Studies (wr 33278) | Trials (wr 33278) | Recent Studies (post-2010) (wr 33278) | Studies (amifostine anhydrous) | Trials (amifostine anhydrous) | Recent Studies (post-2010) (amifostine anhydrous) |
|---|---|---|---|---|---|
| 21 | 0 | 0 | 1,636 | 249 | 247 |
| Protein | Taxonomy | wr 33278 (IC50) | amifostine anhydrous (IC50) |
|---|---|---|---|
| D(3) dopamine receptor | Homo sapiens (human) | 1.929 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fichtinger-Schepman, AM; Nijtmans, LG; Treskes, M; van der Vijgh, WJ | 1 |
| Holwerda, U; Nijtmans, LG; Pinedo, HM; Treskes, M; van der Vijgh, WJ | 1 |
| Holwerda, U; Klein, I; Pinedo, HM; Treskes, M; van der Vijgh, WJ | 1 |
| Fahey, RC; Newton, GL | 1 |
| Fahey, RC; Smoluk, GD; Ward, JF | 1 |
| Bonner, HS; Glover, DJ; Kligerman, MM; Norfleet, AL; Shaw, LM; Turrisi, AT; Weiler, C | 1 |
| Bonner, H; Lieberman, R; Shaw, LM | 1 |
| Charlier, M; Hugot, S; Sabattier, R; Savoye, C; Spotheim-Maurizot, M; Swenberg, C; Sy, D | 1 |
| Capizzi, RL | 1 |
| List, AF | 1 |
| Gerner, EW; List, AF | 1 |
| Gerner, EW; List, AF; Quiñones, HI | 1 |
3 review(s) available for wr 33278 and amifostine anhydrous
| Article | Year |
|---|---|
Pharmacokinetic profile of amifostine.
Topics: Amifostine; Animals; Humans; Mercaptoethylamines; Radiation-Protective Agents | 1996 |
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Topics: Amifostine; Animals; Antineoplastic Agents; Cytoprotection; Drug Evaluation, Preclinical; Humans; Mercaptoethylamines; Neoplasms; Neoplasms, Experimental; Prodrugs; Protective Agents; Radiation-Protective Agents; Tumor Cells, Cultured | 1999 |
Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
Topics: Acute Disease; Amifostine; Animals; Apoptosis; Cytoprotection; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Leukemia; Mercaptoethylamines; Molecular Structure; Myelodysplastic Syndromes; Protective Agents; Spermidine; Spermine | 1999 |
9 other study(ies) available for wr 33278 and amifostine anhydrous
| Article | Year |
|---|---|
Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Topics: Amifostine; Animals; Buffers; Cisplatin; Ditiocarb; DNA; DNA Adducts; Hydrogen-Ion Concentration; Mercaptoethylamines; Salmon; Thiosulfates | 1992 |
The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Topics: Amifostine; Chromatography, High Pressure Liquid; Chromatography, Ion Exchange; Cisplatin; Ditiocarb; Drug Interactions; Drug Stability; Fumarate Hydratase; Glutathione; Kinetics; Mercaptoethylamines; Radiation-Protective Agents; Spectrophotometry, Ultraviolet | 1992 |
The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Topics: Amifostine; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Interactions; Kinetics; Mercaptoethylamines; Radiation-Protective Agents | 1991 |
Measurement of WR-2721, WR-1065, and WR-33278 in plasma.
Topics: Adult; Amifostine; Animals; Female; Humans; Male; Mercaptoethylamines; Methods; Organothiophosphorus Compounds; Radiation-Protective Agents; Rats; Rats, Inbred F344 | 1985 |
Equilibrium dialysis studies of the binding of radioprotector compounds to DNA.
Topics: Amifostine; DNA; Mercaptoethylamines; Radiation-Protective Agents | 1986 |
Human pharmacokinetics of WR-2721.
Topics: Amifostine; Humans; Kinetics; Mercaptoethylamines; Neoplasms; Organothiophosphorus Compounds; Radiation-Protective Agents; Tissue Distribution | 1986 |
Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage.
Topics: Amifostine; Base Sequence; Circular Dichroism; Computer Simulation; DNA Damage; DNA, Bacterial; Fast Neutrons; Mercaptoethylamines; Models, Molecular; Molecular Sequence Data; Nucleic Acid Conformation; Plasmids; Radiation-Protective Agents | 1997 |
Amifostine: a tonic or toxin to myeloid progenitors.
Topics: Amifostine; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Humans; Leukemia, Myeloid; Mercaptoethylamines; Myeloid Progenitor Cells; Radiation-Protective Agents | 2000 |
Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives.
Topics: Amifostine; Biological Transport; Cell Survival; Dose-Response Relationship, Drug; Eflornithine; Gene Expression; Humans; Mercaptoethylamines; Ornithine Decarboxylase Inhibitors; Polyamines; Proteins; Radiation-Protective Agents; Transfection; Tumor Cells, Cultured | 2002 |